Showing 41-50 of 2293 results for "".
Pathway to Success? MS Drug Takes Nrf-2 Pathway for Treatment
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/pathway-to-success-ms-drug-takes-nrf-2-pathway-for-treatment/30774/BG-12 is an oral therapy under regulatory review in the US and Europe for the treatment of MS.Clinical Focus: Vitamin D and MS: Implications for Patient Care
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/clinical-focus-vitamin-d-and-ms-implications-for-patient-care/30859/There are clear non-neurologic medical reasons to avoid hypovitaminosis D and some evidence that vitamin D supplementation can influence the course of MS in deficient patients.Sexual Discomfort: Dealing with Dysfunction in MS and Other Neurological Conditions
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN0509_01-php/30915/Sexual dysfunction can be detrimental to patients with neurodegenerative disease—especially MS. So why aren't patients—and neurologists—talking more about it?MS Minute: A Brief History of MS Care
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-a-brief-history-of-ms-care/31957/“The secret of the care of the patient is in caring for the patient.”—Dr. Francis Peabody- Making the Switch: When and How to Step-Up MS Therapyhttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN1108MS-pdf/30974/Advancements and Considerations in Multiple Sclerosis TherapeuticsOver the past quarter-century, Multiple Sclerosis (MS) treatment has evolved rapidly, marked by the FDA approval of six disease-modifying therapies (DMTs) with several more in development. This acceleration contrasts with the decade-l
MS Minute: Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease/32180/MOGAD, an inflammatory demyelinating disease of the central nervous system, has some overlapping clinical features with NMOSD and MS but is a distinct entity with unique pathologic, clinical, and imaging features.MS Minute: The COVID-19 Vaccine & Vaccine Readiness in MS
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-the-covid-19-vaccine-vaccine-readiness-in-ms/31748/Evidence suggests all people with multiple sclerosis, including those on any class of disease-modifying treatment, can and should be vaccinated against COVID-19.MS Minute: Ibudilast
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-ibudilast/31622/Ibudilast is a phosphodiesterase inhibitor that has shown some benefit for progressive multiple sclerosis in a phase 2 trial.Got a Minute for MS?
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/got-a-minute-for-ms/30286/MS Minute: Menopause and Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minutebrmenopause-and-multiple-sclerosis/32119/Multiple sclerosis and menopause have overlapping symptoms, complicating evaluation of disease progression and care of this population.